Alzheimer Disease
Dosing commenced in Phase IIa trial of PBT2 in early Alzheimer patients
Published in Physician Law Weekly, January 17th, 2007
The PBT2-201-Euro trial is being conducted in seven centers throughout Sweden and will focus on exploring the safety and tolerability of PBT2, Prana's proprietary lead compound, and its effects on the mechanism and progression of the disease, investigating both central and peripheral biomarkers of Alzheimer disease as well as cognition.
The principal investigator for the trial is Professor Lars Lannfelt, MD, PhD, of the department of Public Health/Geriatrics at Uppsala University. Lannfelt and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
Source: Physician Law Weekly (2007-01-17)
More Articles from Physician Law Weekly
- Antibacterial Agents
New Drug Application submitted for investigational antibiotic Doripenem - Arthroplasty
Researchers at Joint Implant Surgeons, Inc. release new data on arthroplasty - Awards
Neuropharma receives Frost & Sullivan International Excellence in Technology award - Breast Cancer
Kodak files with Health Canada for approval of its CR system for mammography - Breast Cancer
Taxotere-based regimens with Herceptin in early-stage HER2 breast cancer raise survival rate - Business Update
Advancis closes private placement of common equity, files application for Pulsys - More from this issue of Physician Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
